Bantam E-Cigarettes Receives FDA PMTA Approval

Dec.27.2022
Bantam E-Cigarettes Receives FDA PMTA Approval
Bantam receives FDA approval for its PMTA application, allowing its nicotine oil products to proceed to scientific review.

Bantam e-cigarettes have received permission from the US FDA for their pre-market tobacco product application (PMTA). The application for Bantam's non-tobacco nicotine e-liquids will now move to the next stage of the PMTA process, undergoing initial scientific review to confirm that all necessary items are included in the application for the FDA's substantive review.


On May 13th, 2022, Bantam submitted an application to the FDA for non-tobacco nicotine e-liquid and is seeking approval for market release from the organization.


Anthony Dillon, spokesperson for Bantam, stated that receiving this acceptance letter reflects Bantam's efforts to provide high-quality, science-based e-liquids for adult consumers while also maintaining our responsibility to restrict access and usage of these products by young people. Bantam continues to support the necessary regulation of e-liquids based on scientific evidence and is proud of our various PMTA advancements. We remain confident in the quality, consistency, and scientific foundation of our products.


Prior to the submission focused on non-tobacco nicotine, Bantam submitted a PMTA for tobacco-derived e-liquids to the FDA in September 2020. The application underwent scientific review in August 2021 and is currently still under FDA consideration.


Earlier this year, this e-liquid manufacturer received an exemption from the United States Postal Service (USPS), allowing the company to ship its e-liquid products to specific e-cigarette retailers and distributors across the United States.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Alan Zhao: What Altria’s on! PLUS Authorization Really Signals About FDA PMTA Enforcement
Alan Zhao: What Altria’s on! PLUS Authorization Really Signals About FDA PMTA Enforcement
In this in-depth commentary for 2Firsts, Alan Zhao examines what Altria’s on! PLUS authorization really signals about FDA PMTA enforcement. Beyond the headline approval, FDA’s language, process design and product choices offer rare insight into how nicotine pouch regulation is taking shape—and what it means for industry compliance, in one of the earliest expert reads of the decision.
Regulations
Dec.20 by 2Firsts Perspectives
Kardinal to Launch Dual Open-System Devices Globally in Q1 2026
Kardinal to Launch Dual Open-System Devices Globally in Q1 2026
Kardinal OS and Syn Signal Strategic Expansion in Open-System ENDS
Dec.31
Canadian Media Investigation: BAT’s Nicotine Pouch ZONNIC Sparks Ongoing Controversy as Regulatory Gaps in Canada Come Under Scrutiny
Canadian Media Investigation: BAT’s Nicotine Pouch ZONNIC Sparks Ongoing Controversy as Regulatory Gaps in Canada Come Under Scrutiny
Canadian outlet Rebel News released a long-form video report examining Canada’s regulatory framework for nicotine pouches, market dynamics, and the approval process of ZONNIC, a product of BAT subsidiary Imperial Tobacco Canada. The report highlights issues involving youth access, regulatory gaps, black-market activity, retailer feedback, and company responses. This article summarizes key points based on the video.
Dec.02 by 2FIRSTS.ai
Imperial Brands launches ZONE nicotine pouches in the UK, covering the core 9–12 mg strength segment
Imperial Brands launches ZONE nicotine pouches in the UK, covering the core 9–12 mg strength segment
Imperial Brands has launched its ZONE nicotine pouches in the UK, targeting the mainstream 9–12 mg nicotine strength segment. The brand debuts with five flavours at a recommended retail price of £6.50 per can. Mint variants currently account for around 70% of UK nicotine pouch sales, while fruit flavours are growing rapidly. ZONE will be distributed primarily through independent retail channels.
Nov.18 by 2FIRSTS.ai
Russia’s Public Chamber official opposes “generational ban” on tobacco sales, citing rights concerns
Russia’s Public Chamber official opposes “generational ban” on tobacco sales, citing rights concerns
Vladislav Grib, deputy secretary of the Public Chamber of the Russian Federation, said a “generational ban” on cigarette sales—restricting sales based on year of birth—would not resolve smoking and would instead lead to human rights violations. He argued older cohorts would buy and share, and the approach would split citizens into two categories.
Jan.08 by 2FIRSTS.ai
Guam checks 277 eligible retailers in 2025; eight found selling tobacco or disposable vapes to minors aged 16–20
Guam checks 277 eligible retailers in 2025; eight found selling tobacco or disposable vapes to minors aged 16–20
he Guam Behavioral Health and Wellness Center said that out of 277 eligible tobacco retailers inspected in 2025, eight were found selling tobacco or disposable e-cigarettes or vapes to minors aged 16–20, and one retailer failed to display the required “No Sale Under 21” prohibition sign.
Jan.05 by 2FIRSTS.ai